Pfizer (NYSE:PFE) Stock Sees Unusually High Call Option Buying

Pfizer Inc. (NYSE:PFE) saw unusually large options trading activity on Wednesday. Stock investors purchased 129,850 call options on the stock. This represents an increase of approximately 23% compared to the average daily volume of 105,297 call options.

Pfizer Stock Performance

Shares of PFE traded up $0.85 during trading hours on Wednesday, hitting $29.22. The company’s stock had a trading volume of 39,310,200 shares, compared to its average volume of 40,282,973. The business has a 50 day simple moving average of $27.81 and a two-hundred day simple moving average of $26.52. Pfizer has a 52-week low of $23.62 and a 52-week high of $29.49. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market cap of $166.53 billion, a price-to-earnings ratio of 38.44, a PEG ratio of 1.92 and a beta of 0.32.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Broad IDWeek 2026 pipeline update: Pfizer plans to present more than 50 abstracts, including 12 oral presentations, covering pneumococcal disease, RSV, COVID-19 and Lyme disease. The volume of upcoming clinical data gives investors multiple potential catalysts beyond the company’s COVID-era products. Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
• Positive Sentiment: Next-generation vaccine progress: Pfizer has begun a Phase 3 trial for a next-generation pediatric pneumococcal vaccine, potentially extending the growth runway for its vaccines business. Investors are also watching Phase 3 Lyme vaccine results and additional real-world vaccine data. Pfizer’s Next-Gen Pneumococcal Shot Enters Key Phase 3 Test
• Positive Sentiment: New external innovation deal: Pfizer’s collaboration and licensing agreement with Enodia Therapeutics gives it access to a Sec61 inhibitor platform and adds a new small-molecule discovery program. Pfizer will oversee clinical, regulatory and commercial development, although the financial and development risks remain significant. What Is Pfizer Really Gaining From Its Sec61 Drug Discovery Deal?
• Positive Sentiment: Income support and improving outlook: Pfizer’s roughly 6% dividend yield, recently declared quarterly dividend of $0.43 per share, positive recent clinical updates and improved earnings guidance make the stock attractive to income-focused investors while the pipeline develops. Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline
• Neutral Sentiment: Risks remain: Commentary highlights Pfizer’s elevated dividend payout ratio, while the median analyst price target of about $27 trails the stock’s recent trading level. These factors may limit further upside unless clinical execution and earnings growth improve. Pfizer Pays Out Over 226% of Earnings

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. Cantor Fitzgerald upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $28.72.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC grew its stake in Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 509 shares during the last quarter. Keb Asset Management LLC acquired a new stake in Pfizer during the 2nd quarter valued at approximately $26,000. Field & Main Bank purchased a new position in shares of Pfizer during the second quarter worth $27,000. Evolution Wealth Management Inc. raised its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the last quarter. Finally, Bullseye Investment Management LLC acquired a new position in Pfizer in the second quarter valued at approximately $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.